Display options
Share it on

J Ophthalmol. 2016;2016:1287847. doi: 10.1155/2016/1287847. Epub 2016 Feb 10.

Pilot Study on Visual Function and Fundus Autofluorescence Assessment in Diabetic Patients.

Journal of ophthalmology

Ana M Calvo-Maroto, José J Esteve-Taboada, Rafael J Pérez-Cambrodí, David Madrid-Costa, Alejandro Cerviño

Affiliations

  1. Optometry Research Group, Department of Optics & Optometry & Vision Sciences, University of Valencia, Burjassot, 46100 Valencia, Spain.
  2. Department of Ophthalmology, Oftalmar, Medimar International Hospital, 03016 Alicante, Spain.

PMID: 26977312 PMCID: PMC4764742 DOI: 10.1155/2016/1287847

Abstract

Purpose. Evaluate optimized fundus autofluorescence (FAF) imaging in early stages of diabetic retinopathy (DR) and relate findings with conventional colour fundus imaging and visual function in diabetic patients and control subjects. Materials and Methods. FAF and colour images were obtained using the CR-2 Plus digital nonmydriatic retinal camera in seven diabetic patients and thirteen control subjects. Visual-Functioning Questionnaire-25 (VFQ-25) and Diabetes Self-Management Questionnaire (DSMQ) were used to assess the quality of life and diabetes self-care. Contrast sensitivity function (CSF) was evaluated with the Vistech 6500 chart. Results. FAF and optimized-FAF imaging showed more retinal alterations related to DR than colour imaging. In diabetic patients, compatible signs with microaneurysms, capillary dilations, and haemorrhages were less numerous in colour imaging than optimized-FAF and FAF imaging in areas analysed. Control subjects at risk of developing DM showed more retinal pigment epithelium defects than those without risk in all retinal areas. Significant differences were not found in VFQ-25 and CSF between diabetic patients and control subjects. Conclusions. FAF and optimized-FAF imaging showed significant alterations related to DR not observed in colour imaging. FAF and optimized-FAF images could be a useful complementary tool for detecting early alterations associated with the development and progression of DR.

References

  1. Arch Ophthalmol. 2001 Jul;119(7):1050-8 - PubMed
  2. Eye (Lond). 2010 Jan;24(1):29-35 - PubMed
  3. J Ophthalmic Vis Res. 2012 Jul;7(3):261-7 - PubMed
  4. J Biomed Opt. 2004 Jan-Feb;9(1):9-21 - PubMed
  5. Ophthalmology. 2003 Sep;110(9):1677-82 - PubMed
  6. Ophthalmology. 2012 May;119(5):1056-65 - PubMed
  7. Invest Ophthalmol Vis Sci. 2012 Jul 26;53(8):4932-9 - PubMed
  8. Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):442-8 - PubMed
  9. J Pediatr Ophthalmol Strabismus. 2011 Mar-Apr;48(2):92-7 - PubMed
  10. Diabetes Care. 1995 Mar;18(3):382-7 - PubMed
  11. Health Qual Life Outcomes. 2008 Nov 07;6:95 - PubMed
  12. J Biomed Opt. 2007 Mar-Apr;12(2):024012 - PubMed
  13. Diabetes Care. 2011 Jan;34 Suppl 1:S62-9 - PubMed
  14. Aging Cell. 2008 Jan;7(1):58-68 - PubMed
  15. J Ophthalmol. 2014;2014:418193 - PubMed
  16. J Ocul Biol Dis Infor. 2010 Jun;3(2):60-3 - PubMed
  17. Diabetes Care. 2003 Sep;26(9):2653-64 - PubMed
  18. Retina. 2008 Mar;28(3):385-409 - PubMed
  19. Klin Oczna. 2009;111(7-9):221-3 - PubMed
  20. Ophthalmology. 2003 Feb;110(2):392-9 - PubMed
  21. Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):729-34 - PubMed
  22. Chin Med J (Engl). 2014;127(8):1423-8 - PubMed
  23. Int J Telemed Appl. 2012;2012:806464 - PubMed
  24. Retina. 2008 Jan;28(1):5-35 - PubMed
  25. Arch Ophthalmol. 1998 Nov;116(11):1496-504 - PubMed
  26. Diabetes Care. 2012 Mar;35(3):556-64 - PubMed
  27. Zhonghua Yan Ke Za Zhi. 2012 Jan;48(1):41-6 - PubMed
  28. Health Qual Life Outcomes. 2013 Aug 13;11:138 - PubMed
  29. Diabetes Care. 2004 Oct;27(10):2540-53 - PubMed
  30. Saudi J Ophthalmol. 2014 Apr;28(2):111-6 - PubMed

Publication Types